Procter & Gamble Health · NSE: PGHL · BSE: 500126
Q1 FY23 results · Apr–Jun 2022
Procter & Gamble Health reported revenue from operations of ₹295.89 crore (up 3.7% from Q1 FY22) and net profit of ₹41.19 crore (up 21.5% from Q1 FY22) for Q1 FY23 (Apr–Jun 2022), on a standalone basis.
| Item | Q1 FY23 | Q1 FY22 | YoY | Q4 FY22 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 295.89 | 285.39 | +3.7% | 267.82 | +10.5% |
| Other income | 3.10 | 2.42 | +28.1% | 2.35 | +31.9% |
| Total income | 298.99 | 287.81 | +3.9% | 270.17 | +10.7% |
| Profit before tax | 54.65 | 43.53 | +25.5% | 64.86 | −15.7% |
| Net profit for the period | 41.19 | 33.89 | +21.5% | 51.16 | −19.5% |
| EPS, basic (₹) | 24.80 | 20.40 | not comparable | 30.80 | not comparable |
| Net margin (%) | 13.9 | 11.9 | 19.1 |
Standalone
- Filed with BSE
- 30 Aug 2022, 17:59 IST
- Board meeting
- 29 Aug 2022
- Period
- 01 Apr 2022 to 30 Jun 2022
- Review status
- Audited
- Source
- XBRL filing on BSE